Silk Road Medical (NSDQ:SILK) posted fourth-quarter results that missed the consensus forecast on Wall Street, citing a second wave of COVID-19 in the last quarter of 2020. The Sunnyvale, Calif.-based company reported losses of -$16.8 million, or -49¢ per share, on sales of $21.1 million for the three months ended Dec. 31, 2020, for a […]
Silk Road Medical Inc.
Silk Road Medical touts results of large TCAR study
Silk Road Medical (NSDQ:SILK) touted results from a comparative effectiveness study of transcarotid artery revascularization (TCAR). Results, published in JAMA Network Open, found that the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events, which are a composite of in-hospital stroke, myocardial infarction or death […]
Silk Road Medical issues voluntary recall of Enroute transcarotid stent system
Silk Road Medical (NSDQ:SILK) announced today that it is voluntarily recalling additional lots of its Enroute transcarotid stent system. Enroute, which is manufactured by Cardinal Health (NYSE:CAH) subsidiary Cordis, has received a total of six product complaints between September 2020 and January 2021 involving an issue in which a tip detaches from the stent delivery system. Additionally, test […]
Silk Road medical adds to executive team
Stroke treatment developer Silk Road Medical (NSDQ:SILK) announced that it appointed a new executive VP of R&D and COO. William Whealon joined as executive VP of research & development, effective immediately, while current CFO Lucas Buchanan will also operate as Silk Road’s COO, effective Oct. 1. Whealon has over two decades of experience in the industry, having […]
Silk Road Medical appoints chief commercial officer
Stroke treatment developer Silk Road Medical (NSDQ:SILK) announced that it promoted Andrew Davis as its new chief commercial officer. In the newly created role at the Sunnyvale, Calif.-based company, Davis is slated to oversee Silk Road Medical’s global commercialization efforts by establishing near-term priorities and setting the long-term strategic direction for the organization, according to a […]
Silk Road Medical closes allotment option
Silk Road Medical (NSDQ:SILK) announced that underwriters fully exercised and closed on additional options to purchase shares in a stock offering. The offering of more than 6.8 million shares included the exercise of the option to purchase more than 1 million additional shares at the public offering price of $39 per share. Silk Road Medical […]
COVID-19 upends medtech’s financial outlook
The uncertain times brought on by the COVID-19 pandemic have affected businesses worldwide, and several sectors of medtech industry are projecting hits to their bottom lines. A number of companies have announced decisions to withdraw financial guidance, cut hours and/or staff, among other major business decisions. Initial impacts of the global pandemic on Wall Street […]
These young medtech companies raised the most money in 2019
Medical device industry insiders may very well remember 2019 as the year that IPOs came back — but another sign that the U.S. economy has left the Great Recession far behind. Among the top investment deals in the space, half involved public offerings, according to the MoneyTree report from PricewaterhouseCoopers (PwC) and CB Insights. Total investments […]
Why your medtech career needs graceful exits
Erica Rogers, the CEO of hot medtech IPO Silk Road Medical (NSDQ:SILK), learned an important career lesson back in the 1990s. After more than 10 years at Boston Scientific, Rogers didn’t want to move from the West Coast to Boston to try to rise up through the company even more. As she recently related to Medsider’s […]
Silk Road Medical ups its stock offering by $31.8 million
Silk Road Medical (NSDQ:SILK) increased a stock offering it registered earlier this week to $191.8 million, according to a regulatory filing. The company’s original registration for $159 million was to fund its transcarotid artery revascularization (TCAR) technology for the treatment of stroke. The Sunnyvale, Calif.-based company is now proposing an offering of 4.8 million shares of its […]
Silk Road Medical proposes $159m stock offering
Silk Road Medical (NSDQ:SILK) has registered a $159 million stock offering to fund its transcarotid artery revascularization (TCAR) technology for the treatment of stroke, according to a regulatory filing. The Sunnyvale, Calif.-based company is proposing an offering of 4.04 million shares of its common stock at a maximum share price of $39.50 each, including 525,000 […]
